Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC.

Thoracic cancer - 1 Aug 2026

Caumeil Marion, Vendrell Julie A, Cabello-Aguilar Simon, Cavaillon Sarah, Thomas Quentin Dominique, Solassol Jérôme

Abstract excerpt

Circulating tumor DNA (ctDNA) monitoring may detect resistance to KRASG12C inhibitors earlier than conventional imaging. However, in the specific context of KRASG12C inhibitors, the temporal relationship between molecular, radiologic, and clinical progression remains poorly characterized. A 66-year-old woman with KRASG12C/STK11/KEAP1-mutant lung adenocarcinoma received second-line adagrasib after progression on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Drug Resistance, Neoplasm

Share to KEAP1 gene

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 42528143
DOI: 10.1111/1759-7714.70313
PMCID: PMC13420328

Genes

KRAS
KEAP1
STK11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC.PMID 42528143Read ↗

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.Semantic proximity Read ↗

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.Semantic proximity Read ↗

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Semantic proximity Read ↗

The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.Semantic proximity Read ↗

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.Semantic proximity Read ↗

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.Semantic proximity Read ↗

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.Semantic proximity Read ↗

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerSemantic proximity Read ↗

Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX studySemantic proximity Read ↗

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.